PE20150775A1 - Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcio - Google Patents
Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcioInfo
- Publication number
- PE20150775A1 PE20150775A1 PE2015000296A PE2015000296A PE20150775A1 PE 20150775 A1 PE20150775 A1 PE 20150775A1 PE 2015000296 A PE2015000296 A PE 2015000296A PE 2015000296 A PE2015000296 A PE 2015000296A PE 20150775 A1 PE20150775 A1 PE 20150775A1
- Authority
- PE
- Peru
- Prior art keywords
- disustituted
- oxazolidinone
- inhibitors
- derivatives
- potassium channel
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 title 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- XWNOUAOTNUVPPW-NRFANRHFSA-N 2-[(4s)-4,5,5-tris(4-fluorophenyl)-2-oxo-1,3-oxazolidin-3-yl]acetamide Chemical compound C1([C@@H]2N(C(OC2(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)CC(=O)N)=CC=C(F)C=C1 XWNOUAOTNUVPPW-NRFANRHFSA-N 0.000 abstract 1
- DZWYJTVGTZAQIB-NRFANRHFSA-N 2-[(4s)-4-(2,4-difluorophenyl)-5,5-bis(4-fluorophenyl)-2-oxo-1,3-oxazolidin-3-yl]acetamide Chemical compound C1([C@@H]2N(C(OC2(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)CC(=O)N)=CC=C(F)C=C1F DZWYJTVGTZAQIB-NRFANRHFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invencion proporciona compuestos que tienen la formula general l: en la que n, R1, R2a, R2b, R3a y R3b tienen los significados aqui definidos, una composicion que contiene los compuestos y metodos de uso de los compuestos. Son compuestos preferidos tenemos: 2-[(S)-4-(2, 4-difluor-fenil)-5, 5-bis-(4-fluor-fenil) -2-oxo-oxazolidin-3-il] -acetamida; 2-[(S)-4, 5, 5-tris-(4-fluor-fenil)-2-oxo-oxazolidin-3-il] - acetamida, entre otros
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190319 | 2012-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150775A1 true PE20150775A1 (es) | 2015-05-21 |
Family
ID=47143594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000296A PE20150775A1 (es) | 2012-10-29 | 2013-10-25 | Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcio |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9611232B2 (es) |
| EP (1) | EP2912034B1 (es) |
| JP (1) | JP6216385B2 (es) |
| KR (1) | KR20150075091A (es) |
| CN (1) | CN104781256B (es) |
| AR (1) | AR093168A1 (es) |
| AU (1) | AU2013339607A1 (es) |
| BR (1) | BR112015003996A2 (es) |
| CA (1) | CA2879249A1 (es) |
| CL (1) | CL2015000906A1 (es) |
| CO (1) | CO7170170A2 (es) |
| CR (1) | CR20150159A (es) |
| EA (1) | EA026161B1 (es) |
| HK (1) | HK1207632A1 (es) |
| IL (1) | IL237331A0 (es) |
| IN (1) | IN2015DN00961A (es) |
| MA (1) | MA38135B1 (es) |
| MX (1) | MX2015002399A (es) |
| PE (1) | PE20150775A1 (es) |
| PH (1) | PH12015500292A1 (es) |
| SG (1) | SG11201500585XA (es) |
| TW (1) | TW201422596A (es) |
| UA (1) | UA114649C2 (es) |
| WO (1) | WO2014067861A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
| EP3941903A1 (en) | 2019-03-22 | 2022-01-26 | Saniona A/S | Novel potassium channel inhibitors |
| CN116368112A (zh) | 2020-09-22 | 2023-06-30 | 萨尼奥纳有限责任公司 | 新型钾通道抑制剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2538424C2 (de) * | 1975-08-29 | 1983-01-05 | Nordmark-Werke Gmbh, 2000 Hamburg | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat |
| DE3687870T2 (de) * | 1985-09-09 | 1993-08-19 | Otsuka Pharma Co Ltd | 2-oxa-isocephemverbindungen, sie enthaltende zusammensetzungen und verfahren zu deren herstellung. |
| KR930703262A (ko) * | 1990-11-06 | 1993-11-29 | 스튜어트 알. 슈터 | 이미다졸리디논 화합물 |
| DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| AU1812197A (en) * | 1996-03-01 | 1997-09-16 | Sankyo Company Limited | Hydroxamic acid derivatives |
| AU760250B2 (en) * | 1998-12-04 | 2003-05-08 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| JP3966693B2 (ja) * | 2000-01-20 | 2007-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素環化合物およびそれらを含んでなる医薬組成物 |
| RU2230060C2 (ru) * | 2000-01-20 | 2004-06-10 | Эйсай Ко., Лтд. | Соединения, фармацевтическая композиция, способ предотвращения гибели нервных клеток, способ профилактики |
| JP4295505B2 (ja) * | 2000-11-22 | 2009-07-15 | バイエル アクチェンゲゼルシャフト | 新規なラクタム置換ピラゾロピリジン誘導体 |
| EP1781635B1 (en) | 2004-07-29 | 2012-06-13 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| US7378530B2 (en) * | 2005-02-22 | 2008-05-27 | Nereus Pharmaceuticals, Inc. | Anti-cancer and anti-microbial 5-membered heterocyclic compounds |
| US20100056637A1 (en) | 2005-12-20 | 2010-03-04 | Icagen, Inc. | Treatment methods using triaryl methane compounds |
| WO2007109098A2 (en) * | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
| AR074558A1 (es) | 2008-12-12 | 2011-01-26 | Solvay Pharm Bv | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 |
| WO2010123997A1 (en) * | 2009-04-22 | 2010-10-28 | Achaogen, Inc. | Carbacephem beta-lactam antibiotics |
-
2013
- 2013-10-25 KR KR1020157011024A patent/KR20150075091A/ko not_active Withdrawn
- 2013-10-25 CA CA2879249A patent/CA2879249A1/en not_active Abandoned
- 2013-10-25 UA UAA201504977A patent/UA114649C2/uk unknown
- 2013-10-25 WO PCT/EP2013/072361 patent/WO2014067861A1/en active Application Filing
- 2013-10-25 BR BR112015003996A patent/BR112015003996A2/pt not_active IP Right Cessation
- 2013-10-25 AU AU2013339607A patent/AU2013339607A1/en not_active Abandoned
- 2013-10-25 MX MX2015002399A patent/MX2015002399A/es unknown
- 2013-10-25 EP EP13783333.1A patent/EP2912034B1/en not_active Not-in-force
- 2013-10-25 SG SG11201500585XA patent/SG11201500585XA/en unknown
- 2013-10-25 JP JP2015538458A patent/JP6216385B2/ja not_active Expired - Fee Related
- 2013-10-25 PE PE2015000296A patent/PE20150775A1/es not_active Application Discontinuation
- 2013-10-25 CN CN201380056503.4A patent/CN104781256B/zh not_active Expired - Fee Related
- 2013-10-25 EA EA201590729A patent/EA026161B1/ru not_active IP Right Cessation
- 2013-10-25 MA MA38135A patent/MA38135B1/fr unknown
- 2013-10-25 IN IN961DEN2015 patent/IN2015DN00961A/en unknown
- 2013-10-28 AR ARP130103922A patent/AR093168A1/es unknown
- 2013-10-28 TW TW102138950A patent/TW201422596A/zh unknown
-
2015
- 2015-01-16 CO CO15008510A patent/CO7170170A2/es unknown
- 2015-02-10 PH PH12015500292A patent/PH12015500292A1/en unknown
- 2015-02-19 IL IL237331A patent/IL237331A0/en unknown
- 2015-03-20 CR CR20150159A patent/CR20150159A/es unknown
- 2015-04-10 CL CL2015000906A patent/CL2015000906A1/es unknown
- 2015-04-29 US US14/699,144 patent/US9611232B2/en not_active Expired - Fee Related
- 2015-08-25 HK HK15108258.3A patent/HK1207632A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015535231A (ja) | 2015-12-10 |
| MA38135B1 (fr) | 2018-11-30 |
| US9611232B2 (en) | 2017-04-04 |
| EA201590729A1 (ru) | 2015-07-30 |
| WO2014067861A1 (en) | 2014-05-08 |
| EP2912034A1 (en) | 2015-09-02 |
| JP6216385B2 (ja) | 2017-10-18 |
| AU2013339607A1 (en) | 2015-02-05 |
| HK1207632A1 (en) | 2016-02-05 |
| TW201422596A (zh) | 2014-06-16 |
| CA2879249A1 (en) | 2014-05-08 |
| CN104781256B (zh) | 2017-09-29 |
| MX2015002399A (es) | 2015-06-10 |
| CN104781256A (zh) | 2015-07-15 |
| KR20150075091A (ko) | 2015-07-02 |
| CR20150159A (es) | 2015-04-30 |
| SG11201500585XA (en) | 2015-04-29 |
| IL237331A0 (en) | 2015-04-30 |
| MA38135A2 (fr) | 2016-11-30 |
| EP2912034B1 (en) | 2017-05-31 |
| BR112015003996A2 (pt) | 2017-07-04 |
| UA114649C2 (uk) | 2017-07-10 |
| AR093168A1 (es) | 2015-05-20 |
| CL2015000906A1 (es) | 2015-09-11 |
| US20150246894A1 (en) | 2015-09-03 |
| IN2015DN00961A (es) | 2015-06-12 |
| EA026161B1 (ru) | 2017-03-31 |
| PH12015500292A1 (en) | 2015-04-20 |
| CO7170170A2 (es) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
| UY32918A (es) | Nuevos compuestos de 2-piridona | |
| SV2009003300A (es) | Nuevos herbicidas | |
| PE20150776A1 (es) | 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b | |
| CR20140079A (es) | Aminoquinazolinas como inhibidores de quinasa | |
| HN2012000263A (es) | Derivados n1-sulfonil-5-fluoropirimidinona | |
| CR20140106A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| CO6630154A2 (es) | Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos | |
| CO6390057A2 (es) | Indazoles oxazol sustituidos como inhibidores de pi3-quinasa | |
| CO6541569A2 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
| ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| ECSP11011098A (es) | Nuevas pirazol-4-n-alcoxicarboxamidas cómo microbicidas. | |
| CR11373A (es) | COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA | |
| CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
| MX386852B (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso. | |
| CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| PE20171099A1 (es) | Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidin-2,4-diona como inhibidores de adamts para el tratamiento de osteoartritis | |
| DOP2011000260A (es) | Pirimidinas fusionadas | |
| UY36749A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
| MX2018003294A (es) | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias. | |
| ECSP11011245A (es) | Novedosos herbicidas | |
| PE20160801A1 (es) | Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos | |
| AR065714A1 (es) | Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida | |
| ECSP099827A (es) | Herbicidas novedosos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |